Addex TherapeuticsFRA:APE -13.95% PB Ratio is 1.23 as of Jun. 29, 2026, which is 15% below its 10-year median of 1.45. The stock has 6 warning signs investors should review. Among 1,232 Biotechnology companies, Addex Therapeutics ranks better than 70.21% on this metric.
Addex Therapeutics Ltd stock PB Ratio (=1.56) is close to 2-year high of 1.56.
The historical rank and industry rank for Addex Therapeutics's PB Ratio or its related term are showing as below:
FRA:APE'
s PB Ratio Range Over the Past 10 Years
Min: 0.4 Med: 1.45 Max: 7.97
Current: 1.56
During the past 13 years, Addex Therapeutics's highest PB Ratio was 7.97. The lowest was 0.40. And the median was 1.45.
FRA:APE's PB Ratio is ranked better than 70.21% of 1232
companies
in the Biotechnology industry
Industry Median: 2.835
vs FRA:APE: 1.56
During the past 12 months, Addex Therapeutics's average Book Value Per Share Growth Rate was -66.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -14.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -42.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -11.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Addex Therapeutics was 269.60% per year. The lowest was -71.90% per year. And the median was -39.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Addex Therapeutics PB Ratio Related Terms
Addex Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Addex Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Addex Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Addex Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Addex Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Addex Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Addex Therapeutics (FRA:APE) has a PB Ratio of 1.23 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Addex Therapeutics and its competitors. This is 15% below median its historical median of 1.45. Over the past decade, Addex Therapeutics' PB Ratio has ranged from 0.40 to 7.97. According to the industry distribution chart, Addex Therapeutics ranks #367 out of 1232 companies in the Biotechnology industry, placing it in the top 29.8%.
Is Addex Therapeutics' PB Ratio too high?
Addex Therapeutics' current PB Ratio of 1.23 is 15% below median its 10-year median of 1.45. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 7.97. The Biotechnology industry median PB Ratio is 2.84. Addex Therapeutics' value of 1.23 is 56.6% below this industry median. Based on the distribution chart, Addex Therapeutics ranks #367 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint.
How does Addex Therapeutics' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Addex Therapeutics ranks #367 out of 1232 companies for PB Ratio. This puts Addex Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.84. Addex Therapeutics' value of 1.23 is 56.6% below this benchmark. Historically, Addex Therapeutics' own PB Ratio has ranged from 0.40 to 7.97 over the past decade. While the company's 10-year median is 1.45 vs. the industry median of 2.84, Addex Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.84, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Addex Therapeutics's current PB Ratio of 1.23 is 56.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Addex Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Addex Therapeutics's current PB Ratio is 1.23, which is 15% below median its own 10-year median of 1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Addex Therapeutics (FRA:APE) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.04 — trading 270% above its estimated fair value. The current PB Ratio is 1.23, which is 15% below median its 10-year median of 1.45 and 56.6% below the Biotechnology industry median of 2.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE), the current PB Ratio is 1.23 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APE has been successfully added to your 